Meeting
2021 ASCO Annual Meeting
First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).
Authors
Karen A. Autio
Memorial Sloan Kettering Cancer Center, New York, NY
Karen A. Autio , Celestia S. Higano , Luke T. Nordquist , Leonard Joseph Appleman , Tian Zhang , Xinhua Zhu , Hani M. Babiker , Nicholas J. Vogelzang , Sandip Prasad , Michael Thomas Schweizer , Stephane Billotte , Joseph Binder , Nora Cavazos , Ruifeng Li , Kam Chan , Helen Cho , Michael Dermyer , Robert Hollingsworth , Kenneth Alan Kern , Daniel P. Petrylak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02616185
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2612)
DOI
10.1200/JCO.2021.39.15_suppl.2612
Abstract #
2612
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.
First Author: Jason J. Luke
Poster
2020 ASCO Virtual Scientific Program
A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.
First Author: Liv Cecilie Vestrheim Thomsen
Poster
2018 ASCO Annual Meeting
A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1).
First Author: Jason M. Redman
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna